(no text — see the shared post below)

VESALIUS-CV: Repatha cut first heart attack or stroke 25% in high-risk primary prevention
Summarises VESALIUS-CV in 12,000+ high-risk patients without prior MI or stroke (median age 66, LDL-C >=90 mg/dL on therapy). Adding evolocumab cut 3-point MACE 25% over ~4.5 years, with LDL-C reduced about 55% to a median 45 mg/dL versus 109 mg/dL on placebo.



